Mild-heat-inducible sequentially released liposomal complex remodels the tumor microenvironment and reinforces anti-breast-cancer therapy

2020 ◽  
Vol 8 (14) ◽  
pp. 3916-3925 ◽  
Author(s):  
Yue Qin ◽  
Tingting Liu ◽  
Mengfei Guo ◽  
Yuping Liu ◽  
Congyan Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Microenvironment ◽  
Cancer Therapy ◽  
Drug Release ◽  
Breast Cancer Therapy ◽  
Mild Heat

Heat-responsive drug release helps celastrol & STS-coloaded liposome activate the cascade of TME normalization and enhances the anti-tumor efficacy.

Heparanase-driven sequential released nanoparticles for ferroptosis and tumor microenvironment modulations synergism in breast cancer therapy

Biomaterials ◽  
2021 ◽  
Vol 266 ◽  
pp. 120429
Author(s):  
Jun Zhang ◽  
Jie Yang ◽  
Tiantian Zuo ◽  
Siyu Ma ◽  
Nadira Xokrat ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Microenvironment ◽  
Cancer Therapy ◽  
Breast Cancer Therapy

CDK1 in Breast Cancer: Implications for Theranostic Potential

2020 ◽  
Vol 20 (7) ◽  
pp. 758-767 ◽  
Author(s):  
Sepideh Izadi ◽  
Afshin Nikkhoo ◽  
Mohammad Hojjat-Farsangi ◽  
Afshin Namdar ◽  
Gholamreza Azizi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Microenvironment ◽  
Cancer Therapy ◽  
Cancer Progression ◽  
Cell Cycle Progression ◽  
Cancer Therapeutics ◽  
Detection Methods ◽  
Breast Cancer Therapy ◽  
Promising Target ◽  
Anti Cancer

Breast cancer has been identified as one of the main cancer-related deaths among women during some last decades. Recent advances in the introduction of novel potent anti-cancer therapeutics in association with early detection methods led to a decrease in the mortality rate of breast cancer. However, the scenario of breast cancer is yet going on and further improvements in the current anti-cancer therapeutic approaches are needed. Several factors are present in the tumor microenvironment which help to cancer progression and suppression of anti-tumor responses. Targeting these cancer-promoting factors in the tumor microenvironment has been suggested as a potent immunotherapeutic approach for cancer therapy. Among the various tumorsupporting factors, Cyclin-Dependent Kinases (CDKs) are proposed as a novel promising target for cancer therapy. These factors in association with cyclins play a key role in cell cycle progression. Dysregulation of CDKs which leads to increased cell proliferation has been identified in various cancers, such as breast cancer. Accordingly, the development and use of CDK-inhibitors have been associated with encouraging results in the treatment of breast cancer. However, it is unknown that the inhibition of which CDK is the most effective strategy for breast cancer therapy. Since the selective blockage of CDK1 alone or in combination with other therapeutics has been associated with potent anti-cancer outcomes, it is suggested that CDK1 may be considered as the best CDK target for breast cancer therapy. In this review, we will discuss the role of CDK1 in breast cancer progression and treatment.

Diagnostic and drug release systems based on microneedle arrays in breast cancer therapy

2021 ◽  
Author(s):  
Suliman Khan ◽  
Anwarul Hasan ◽  
Farnoosh Attar ◽  
Mohammad Mahdi Nejadi Babadaei ◽  
Hojjat Alizadeh Zeinabad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Drug Release ◽  
Breast Cancer Therapy ◽  
Microneedle Arrays

A tumor microenvironment (TME)-responsive nanoplatform for systemic saporin delivery and effective breast cancer therapy

2021 ◽  
Author(s):  
Qian Shen ◽  
Lei Xu ◽  
Rong Li ◽  
Guang Wu ◽  
Senlin Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Microenvironment ◽  
Cancer Therapy ◽  
Tumor Growth ◽  
Intracellular Delivery ◽  
Ph Responsive ◽  
Breast Cancer Therapy ◽  
Effective Inhibition ◽  
Inhibition Of Tumor Growth

A robust TME pH-responsive nanoplatform was herein developed. This nanoplatform could significantly improve intracellular delivery of cytotoxic saporin to achieve an effective inhibition of tumor growth of breast cancer.

Liposomes can minimize cardiotoxicity, address drug resistance, and improve overall drug release profiles in breast cancer

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Cancer Therapy ◽  
Drug Release ◽  
Cancer Patients ◽  
Chemotherapeutic Drugs ◽  
Breast Cancer Patients ◽  
Breast Cancer Therapy ◽  
Experimental Development ◽  
Release Profiles

Following the demand for novel techniques for breast cancer therapy, the experimental development of liposome delivery systems is moving rapidly. There is, however, no clear concept or road map for designing the unique formulation of the liposome for breast cancer. Most papers select targeting and triggering modalities based on molecular subtypes of the tumor and existing conventional therapy. Although conventional liposome-formulated chemotherapeutic drugs have been widely used in clinical practice in the treatment of breast cancer, clinical acceptance of these innovative liposome formulations poses some hurdles. When synthesizing such liposomes, the triggering mechanisms must be further investigated. For example, for light-triggered liposomes, the phospholipid component must be selected depending on photo-induced processes. Unsaturated phospholipids would be used when using a photochemical pathway, such as a photo-oxidative reaction. In addition, the active components in the triggerable liposome formulation must be modified to balance healthy tissue benefits and dangers.From the perspective of therapeutic applications, future development of liposome technology will help long-term breast cancer patients. Many studies have demonstrated that various drug-charged liposome architectures can minimize cardiotoxicity, address drug resistance, and improve overall drug release profiles. These liposomes also present opportunities for site-specific therapy by modifying the liposome surface with targeted ligands, lowering non-specific effects of traditional chemotherapeutic drugs. The new generation of triggering characteristics of liposomes enables much more precise management of payload release, greatly enhancing therapy outcomes for breast cancer patients. Liposome formulations can widen the spectrum of drug/gene delivery possibilities for breast cancer therapy, addressing critical medication toxicity concerns and limited therapeutic effectiveness.

Sign in / Sign up

Export Citation Format

Share Document